# Vicore Pharma Holding AB (VCRE) fundamentals

Data as of 2026-11-10. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.35, market value $320 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Vicore Pharma Holding AB reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 64.2×**. Each dollar of revenue is priced at 64.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 0.3×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **Free-cash-flow yield: -144.4%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 100.0%**. Vicore Pharma Holding AB keeps 100.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Return on equity: -43.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -41.4%**. Each dollar of assets produces -41.4% of profit.

## Growth
- **Revenue growth (1 yr): -96.5%**. Revenue fell 96.5% over the last year.
- **EPS growth (1 yr): -61.8%**. Earnings per share fell 61.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Interest coverage: -21.9×**. Operating profit covers interest only -21.9×: fragile.
- **Current ratio: 10.28** (quick 10.28). Current assets cover the next year's liabilities 10.28 times.
- **Altman Z-score: 2.66**. A Z-score of 2.66 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Vicore Pharma Holding AB does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (2 analysts). 2 analysts cover Vicore Pharma Holding AB; the consensus is strong_buy, with an average price target of $30.37 (+168% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -36.2%** (44.0% above the low). Trading 36% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 66**. An RSI of 66 is neutral.
- **Beta (1 yr): 0.11** (volatility 56%). Beta of 0.11 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VCRE · Page: https://foliofundamentals.com/stocks/vcre

Not investment advice.